{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:16:26Z","timestamp":1791252986486,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00467-022-05502-8","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T01:19:53Z","timestamp":1648516793000},"page":"2733-2742","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Comparison of nafamostat mesilate to citrate anticoagulation in pediatric continuous kidney replacement therapy"],"prefix":"10.1007","volume":"37","author":[{"given":"Mai J.","family":"Miyaji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Ide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiko","family":"Maeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli A.","family":"Krallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Lazear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart L.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"key":"5502_CR1","unstructured":"(2012) Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group - KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int suppl 2:1\u2013138"},{"key":"5502_CR2","doi-asserted-by":"crossref","unstructured":"Rodriguez K, Srivaths PR, Tal L, Watson MN, Riley AA, Himes RW, Desai MS, Braun MC, Akcan Arikan A (2017) Regional citrate anticoagulation for continuous renal replacement therapy in pediatric patients with liver failure. PLoS One 12:e0182134","DOI":"10.1371\/journal.pone.0182134"},{"key":"5502_CR3","doi-asserted-by":"publisher","first-page":"R162","DOI":"10.1186\/cc11485","volume":"16","author":"C Schultheiss","year":"2012","unstructured":"Schultheiss C, Saugel B, Phillip V, Thies P, Noe S, Mayr U, Haller B, Einwachter H, Schmid RM, Huber W (2012) Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study. Crit Care 16:R162","journal-title":"Crit Care"},{"key":"5502_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13054-019-2317-9","volume":"23","author":"W Zhang","year":"2019","unstructured":"Zhang W, Bai M, Yu Y, Li L, Zhao L, Sun S, Chen X (2019) Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis. Crit Care 23:22","journal-title":"Crit Care"},{"key":"5502_CR5","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s13054-017-1870-3","volume":"21","author":"M Klingele","year":"2017","unstructured":"Klingele M, Stadler T, Fliser D, Speer T, Groesdonk HV, Raddatz A (2017) Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction. Crit Care 21:294","journal-title":"Crit Care"},{"key":"5502_CR6","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1177\/0885066617701068","volume":"34","author":"JN Tan","year":"2019","unstructured":"Tan JN, Haroon SWP, Mukhopadhyay A, Lau T, Murali TM, Phua J, Tan ZY, Lee N, Chua HR (2019) Hyperlactatemia predicts citrate intolerance with regional citrate anticoagulation during continuous renal replacement therapy. J Intensive Care Med 34:418\u2013425","journal-title":"J Intensive Care Med"},{"key":"5502_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/cc11645","volume":"16","author":"HM Oudemans-van Straaten","year":"2012","unstructured":"Oudemans-van Straaten HM, Ostermann M (2012) Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice. Crit Care 16:249","journal-title":"Crit Care"},{"key":"5502_CR8","doi-asserted-by":"publisher","first-page":"852","DOI":"10.3389\/fonc.2019.00852","volume":"9","author":"X Chen","year":"2019","unstructured":"Chen X, Xu Z, Zeng S, Wang X, Liu W, Qian L, Wei J, Yang X, Shen Q, Gong Z, Yan Y (2019) The molecular aspect of antitumor effects of protease inhibitor nafamostat mesylate and its role in potential clinical applications. Front Oncol 9:852","journal-title":"Front Oncol"},{"key":"5502_CR9","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3109\/08860220903180616","volume":"31","author":"JW Yang","year":"2009","unstructured":"Yang JW, Han BG, Kim BR, Lee YH, Kim YS, Yu JM, Choi SO (2009) Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage. Ren Fail 31:668\u2013675","journal-title":"Ren Fail"},{"key":"5502_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1080\/09537109976040","volume":"10","author":"I Fuse","year":"1999","unstructured":"Fuse I, Higuchi W, Toba K, Aizawa Y (1999) Inhibitory mechanism of human platelet aggregation by nafamostat mesilate. Platelets 10:212\u2013218","journal-title":"Platelets"},{"key":"5502_CR11","doi-asserted-by":"publisher","first-page":"571","DOI":"10.5301\/IJAO.2011.8535","volume":"34","author":"Y Maruyama","year":"2011","unstructured":"Maruyama Y, Yoshida H, Uchino S, Yokoyama K, Yamamoto H, Takinami M, Hosoya T (2011) Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study. Int J Artif Organs 34:571\u2013576","journal-title":"Int J Artif Organs"},{"key":"5502_CR12","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s001340050892","volume":"25","author":"ZJ Hu","year":"1999","unstructured":"Hu ZJ, Iwama H, Suzuki R, Kobayashi S, Akutsu I (1999) Time course of activated coagulation time at various sites during continuous haemodiafiltration using nafamostat mesilate. Intensive Care Med 25:524\u2013527","journal-title":"Intensive Care Med"},{"key":"5502_CR13","doi-asserted-by":"crossref","unstructured":"Lee YK, Lee HW, Choi KH, Kim BS (2014) Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS One 9:e108737","DOI":"10.1371\/journal.pone.0108737"},{"key":"5502_CR14","doi-asserted-by":"crossref","unstructured":"Choi JY, Kang YJ, Jang HM, Jung HY, Cho JH, Park SH, Kim YL, Kim CD (2015) Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine 94:e2392","DOI":"10.1097\/MD.0000000000002392"},{"key":"5502_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3109\/0886022X.2011.647293","volume":"34","author":"NN Baek","year":"2012","unstructured":"Baek NN, Jang HR, Huh W, Kim YG, Kim DJ, Oh HY, Lee JE (2012) The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. Ren Fail 34:279\u2013285","journal-title":"Ren Fail"},{"key":"5502_CR16","doi-asserted-by":"publisher","first-page":"208","DOI":"10.5301\/ijao.5000191","volume":"36","author":"SD Hwang","year":"2013","unstructured":"Hwang SD, Hyun YK, Moon SJ, Lee SC, Yoon SY (2013) Nafamostat mesilate for anticoagulation in continuous renal replacement therapy. Int J Artif Organs 36:208\u2013216","journal-title":"Int J Artif Organs"},{"key":"5502_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5301\/ijao.5000465","volume":"39","author":"S Makino","year":"2016","unstructured":"Makino S, Egi M, Kita H, Miyatake Y, Kubota K, Mizobuchi S (2016) Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy. Int J Artif Organs 39:16\u201321","journal-title":"Int J Artif Organs"},{"key":"5502_CR18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3339\/jkspn.2014.18.2.98","volume":"18","author":"SC Lee","year":"2014","unstructured":"Lee SC, Cho H (2014) The use of nafamostat mesilate as an anticoagulant during continuous renal replacement therapy for children with a high risk of bleeding. J Korean Soc Pediatr Nephrol 18:98\u2013105","journal-title":"J Korean Soc Pediatr Nephrol"},{"key":"5502_CR19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00134-002-1601-2","volume":"29","author":"Slater A, Shann F, Pearson G, Paediatric Index of Mortality Study Group","year":"2003","unstructured":"Slater A, Shann F, Pearson G, Paediatric Index of Mortality Study Group (2003) PIM2: a revised version of the Paediatric Index of Mortality. Intensive Care Med 29:278\u2013285","journal-title":"Intensive Care Med"},{"key":"5502_CR20","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.ekir.2020.12.010","volume":"6","author":"SL Goldstein","year":"2021","unstructured":"Goldstein SL, Askenazi DJ, Basu RK, Selewski DT, Paden ML, Krallman KA, Kirby CL, Mottes TA, Terrell T, Humes HD (2021) Use of the selective cytopheretic device in critically ill children. Kidney Int Rep 6:775\u2013784","journal-title":"Kidney Int Rep"},{"key":"5502_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","volume":"117","author":"HA Sampson","year":"2006","unstructured":"Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, Brown SG, Camargo CA Jr, Cydulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD Jr, Hepner DL, Lewis LM, Lieberman PL, Metcalfe DD, O\u2019Connor R, Muraro A, Rudman A, Schmitt C, Scherrer D, Simons FE, Thomas S, Wood JP, Decker WW (2006) Second symposium on the definition and management of anaphylaxis: summary report\u2013Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 117:391\u2013397","journal-title":"J Allergy Clin Immunol"},{"key":"5502_CR22","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/ndt\/gfh817","volume":"20","author":"PD Brophy","year":"2005","unstructured":"Brophy PD, Somers MJ, Baum MA, Symons JM, McAfee N, Fortenberry JD, Rogers K, Barnett J, Blowey D, Baker C, Bunchman TE, Goldstein SL (2005) Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT). Nephrol Dial Transplant 20:1416\u20131421","journal-title":"Nephrol Dial Transplant"},{"key":"5502_CR23","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/s00134-015-4099-0","volume":"41","author":"M Bai","year":"2015","unstructured":"Bai M, Zhou M, He L, Ma F, Li Y, Yu Y, Wang P, Li L, Jing R, Zhao L, Sun S (2015) Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs. Intensive Care Med 41:2098\u20132110","journal-title":"Intensive Care Med"},{"key":"5502_CR24","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00467-017-3694-4","volume":"32","author":"P Raymakers-Janssen","year":"2017","unstructured":"Raymakers-Janssen P, Lilien M, van Kessel IA, Veldhoen ES, Wosten-van Asperen RM, van Gestel JPJ (2017) Citrate versus heparin anticoagulation in continuous renal replacement therapy in small children. Pediatr Nephrol 32:1971\u20131978","journal-title":"Pediatr Nephrol"},{"key":"5502_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12882-017-0445-5","volume":"18","author":"M Brain","year":"2017","unstructured":"Brain M, Winson E, Roodenburg O, McNeil J (2017) Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis. BMC Nephrol 18:69","journal-title":"BMC Nephrol"},{"key":"5502_CR26","doi-asserted-by":"publisher","first-page":"c94","DOI":"10.1159\/000072492","volume":"94","author":"S Uchino","year":"2003","unstructured":"Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R (2003) Pre-dilution vs. post-dilution during continuous veno-venous hemofiltration: impact on filter life and azotemic control. Nephron Clin Pract 94:c94-98","journal-title":"Nephron Clin Pract"},{"key":"5502_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000083938","volume":"23","author":"PH van der Voort","year":"2005","unstructured":"van der Voort PH, Gerritsen RT, Kuiper MA, Egbers PH, Kingma WP, Boerma EC (2005) Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purif 23:175\u2013180","journal-title":"Blood Purif"},{"key":"5502_CR28","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1177\/039139880703001212","volume":"30","author":"R Hackbarth","year":"2007","unstructured":"Hackbarth R, Bunchman TE, Chua AN, Somers MJ, Baum M, Symons JM, Brophy PD, Blowey D, Fortenberry JD, Chand D, Flores FX, Alexander SR, Mahan JD, McBryde KD, Benfield MR, Goldstein SL (2007) The effect of vascular access location and size on circuit survival in pediatric continuous renal replacement therapy: a report from the PPCRRT registry. Int J Artif Organs 30:1116\u20131121","journal-title":"Int J Artif Organs"},{"key":"5502_CR29","first-page":"225","volume":"16","author":"WJ Dunn","year":"2014","unstructured":"Dunn WJ, Sriram S (2014) Filter lifespan in critically ill adults receiving continuous renal replacement therapy: the effect of patient and treatment-related variables. Crit Care Resusc 16:225\u2013231","journal-title":"Crit Care Resusc"},{"key":"5502_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000477609","volume":"42","author":"M Miklaszewska","year":"2017","unstructured":"Miklaszewska M, Korohoda P, Zachwieja K, Kobylarz K, Stefanidis CJ, Sobczak A, Drozdz D (2017) Filter size not the anticoagulation method is the decisive factor in continuous renal replacement therapy circuit survival. Kidney Blood Press Res 42:327\u2013337","journal-title":"Kidney Blood Press Res"},{"key":"5502_CR31","doi-asserted-by":"publisher","first-page":"114","DOI":"10.5090\/kjtcs.2018.51.2.114","volume":"51","author":"SJ Han","year":"2018","unstructured":"Han SJ, Han W, Song HJ, Kim CS, Jeong SM, Kang MW (2018) Validation of nafamostat mesilate as an anticoagulant in extracorporeal membrane oxygenation: a large-animal experiment. Korean J Thorac Cardiovasc Surg 51:114\u2013121","journal-title":"Korean J Thorac Cardiovasc Surg"},{"key":"5502_CR32","doi-asserted-by":"publisher","first-page":"595","DOI":"10.5301\/ijao.5000451","volume":"38","author":"JH Park","year":"2015","unstructured":"Park JH, Her C, Min HK, Kim DK, Park SH, Jang HJ (2015) Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation. Int J Artif Organs 38:595\u2013599","journal-title":"Int J Artif Organs"},{"key":"5502_CR33","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.athoracsur.2016.01.044","volume":"102","author":"JY Lim","year":"2016","unstructured":"Lim JY, Kim JB, Choo SJ, Chung CH, Lee JW, Jung SH (2016) Anticoagulation during extracorporeal membrane oxygenation; nafamostat mesilate versus heparin. Ann Thorac Surg 102:534\u2013539","journal-title":"Ann Thorac Surg"},{"key":"5502_CR34","unstructured":"Murase M, Usui A, Tomita Y, Maeda M, Koyama T, Abe T (1993) Nafamostat mesilate reduces blood loss during open heart surgery. Circulation 88:II432\u2013436"},{"key":"5502_CR35","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/1744-9987.12357","volume":"20","author":"K Sawada","year":"2016","unstructured":"Sawada K, Ohdo M, Ino T, Nakamura T, Numata T, Shibata H, Sakou J, Kusada M, Hibi T (2016) Safety and tolerability of nafamostat mesilate and heparin as anticoagulants in leukocytapheresis for ulcerative colitis: post hoc analysis of a large-scale, prospective, observational study. Ther Apher Dial 20:197\u2013204","journal-title":"Ther Apher Dial"},{"key":"5502_CR36","first-page":"E30","volume":"63","author":"Y Miyatake","year":"2017","unstructured":"Miyatake Y, Makino S, Kubota K, Egi M, Mizobuchi S (2017) Association between intra-circuit activated clotting time and incidence of bleeding complications during continuous renal replacement therapy using nafamostat mesilate: a retrospective pilot observational study. Kobe J Med Sci 63:E30\u2013E36","journal-title":"Kobe J Med Sci"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05502-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-022-05502-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05502-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T07:18:34Z","timestamp":1663658314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-022-05502-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["5502"],"URL":"https:\/\/doi.org\/10.1007\/s00467-022-05502-8","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"assertion":[{"value":"6 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MJM serves as a consultant to Lowell Therapeutics, Inc, which has licensed NM in the US. At the current time, NM is not approved for marketing in the US. Lowell did not have input into the design of this study, access to the raw data or development of any aspect of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}